

<SUPPLEMENTAL MATERIAL>

Table S1 Antibody development in the men and women of VOLTAIRE-RA

Status	Adalimumab-adbm (n=324)		Adalimumab RP (n=321)	
	Men (n=57)	Women (n=267)	Men (n=52)	Women (n=269)
Antibody first detectable				
ADA	Week 1	Baseline	Baseline	Baseline
nAb	Week 2	Baseline	Baseline	Baseline
ADA titre at primary endpoint, mean (SD) [median: Q1,Q3]	27.7 (37.0) at W12	58.0 (98.7) at W12	503.3 (1922.6) at W12	322.8 (1084.6) at W12
	[8: 4, 32]	[16: 4, 64]	[6: 6,64]	[16: 4, 64]
	122.8 (250.0) at W24	168.4 (804.2) at W24	195.4 (339.4) at W24	315.6 (1704.3) at W24
	[32: 4, 64]	[32: 8, 128]	[64: 16, 64]	[32: 8, 128]
Proportion of patients with antibodies over time*				
ADA positive				
Baseline	0% (0/57)	4.1% (11/266)	11.5% (6/52)	5.6% (15/269)
Week 1	1.9% (1/53)	6.4% (17/264)	15.7% (8/51)	8.1% (21/260)
Week 2	3.8% (2/53)	11.3% (30/265)	13.7% (7/51)	16.5% (44/267)
Week 4	12.7% (7/55)	21.6% (57/264)	23.5% (12/51)	19.2% (51/265)
Week 12	24.5% (13/53)	34.0% (88/259)	38.3% (18/47)	34.2% (88/257)
Week 24	38.0% (19/50)	44.7% (110/246)	53.2% (25/47)	46.9% (119/254)
Week 40	37.0% (17/46)	42.5% (102/240)	52.3% (23/44)	43.4% (105/242)
Week 48	37.5% (18/48)	42.8% (101/236)	51.2% (22/43)	41.0% (98/239)
nAb positive				
Baseline	0% (0/57)	3.4% (9/266)	9.6% (5/52)	4.1% (11/269)
Week 1	0% (0/53)	3.4% (9/264)	5.9% (3/51)	4.2% (11/260)
Week 2	1.9% (1/53)	3.4% (9/265)	13.7% (7/51)	6.7% (18/267)
Week 4	3.6% (2/55)	7.2% (19/264)	9.8% (5/51)	7.2% (19/265)
Week 12	7.5% (4/53)	13.5% (35/259)	21.3% (10/47)	16.0% (41/257)
Week 24	14.0% (7/50)	16.7% (41/246)	25.5% (12/47)	20.1% (51/254)
Week 40	6.5% (3/46)	14.2% (34/240)	20.5% (9/44)	16.1% (39/242)
Week 48	14.6% (7/48)	20.3% (48/236)	25.6% (11/43)	16.3% (39/239)

*Reported in the randomised population at baseline.

ADA, anti-drug antibody; nAb, neutralising antibody; RA, rheumatoid arthritis; RP, reference product; SD, standard deviation; W, week.

Table S2 Antibody development in the men and women of VOLTAIRE-CD

Status	Adalimumab-adbm (n=72)		Adalimumab RP (n=75)	
	Men (n=39)	Women (n=33)	Men (n =44)	Women (n=31)
Antibody first detectable				
ADA	Baseline	Baseline	Week 4	Week 4
nAb	Week 4	Week 4	Week 24	Week 4
ADA titre at primary endpoint, mean (SD) [median: Q1, Q3]	1095.0 (2873.0) at W4 [10: 1.5, 272]	51.7 (100.3) at W4 [16: 4, 16]	32.5 (44.6) at W4 [32.5: 1, 64]	2.5 (2.1) at W4 [10: 3, 16]
Proportion of patients with antibodies over time				
ADA positive				
Baseline	5.4% (2/37)	3.1% (1/32)	0% (0/43)	0% (0/31)
Week 4	21.6% (8/37)	19.4% (6/31)	4.8% (2/42)	6.5% (2/31)
Week 24	65.6% (21/32)	74.1% (20/27)	32.4% (11/34)	63.0% (17/27)
Week 48	64.3% (18/28)	62.5% (15/24)	37.5% (12/32)	70.8% (17/24)
nAb positive				
Baseline	0% (0/37)	0% (0/32)	0% (0/43)	0% (0/31)
Week 4	10.8% (4/37)	6.5% (2/31)	0% (0/42)	6.5% (2/31)
Week 24	31.3% (10/32)	40.7% (11/27)	14.7% (5/34)	33.3% (9/27)
Week 48	25.0% (7/28)	25.0% (6/24)	15.6% (5/32)	25.0% (6/24)

ADA, anti-drug antibody; CD, Crohn’s disease; nAb, neutralising antibody; RP, reference product; SD, standard deviation; W, week.

Table S3. Antibody development in the men and women of VOLTAIRE-PsO.

Status	Adalimumab-adbm (n=159)		Adalimumab RP (n=158)	
	Men (n=101)	Women (n=58)	Men (n=102)	Women (n=56)
Antibody first detectable				
ADA	Baseline	Baseline	Baseline	Baseline
nAb	Baseline	Week 16	Baseline	Baseline
ADA titre at primary endpoint, median (range) [Q1, Q3]	32 (1–16,384) at W16 [16, 128]	48 (1–1024) at W16 [32, 128]	32 (2–2048) at W16 [16, 128]	32 (2–16,384) at W16 [16, 64]
Proportion of patients with antibodies over time				
ADA positive				
Baseline	12.9% (13/101)	6.9% (4/58)	12.7% (13/102)	7.1% (4/56)
Week 16	69.9% (65/93)	65.5% (36/55)	68.0% (96/97)	78.8% (41/52)
Week 24	76.8% (73/95)	72.7% (40/55)	76.1% (70/92)	81.1% (43/53)
nAb positive				
Baseline	1.0% (1/101)	0% (0/58)	2.0% (2/102)	1.8% (1/56)
Week 16	54.8% (51/93)	52.7% (29/55)	50.5% (49/97)	65.4% (34/52)
Week 24	54.7% (52/95)	49.1% (27/55)	52.2% (48/92)	66.0% (35/53)

ADA, anti-drug antibody; nAb, neutralising antibody; PsO, chronic plaque psoriasis; RP, reference product; W, week.